Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Cholesterol Metabolism: A Potential Therapeutic Target in Glioblastoma.

Ahmad F, Sun Q, Patel D, Stommel JM.

Cancers (Basel). 2019 Jan 26;11(2). pii: E146. doi: 10.3390/cancers11020146. Review.

2.

CRISPR/Cas9-mediated gene knockout is insensitive to target copy number but is dependent on guide RNA potency and Cas9/sgRNA threshold expression level.

Yuen G, Khan FJ, Gao S, Stommel JM, Batchelor E, Wu X, Luo J.

Nucleic Acids Res. 2017 Nov 16;45(20):12039-12053. doi: 10.1093/nar/gkx843.

3.

Global Inhibition with Specific Activation: How p53 and MYC Redistribute the Transcriptome in the DNA Double-Strand Break Response.

Porter JR, Fisher BE, Baranello L, Liu JC, Kambach DM, Nie Z, Koh WS, Luo J, Stommel JM, Levens D, Batchelor E.

Mol Cell. 2017 Sep 21;67(6):1013-1025.e9. doi: 10.1016/j.molcel.2017.07.028. Epub 2017 Aug 31.

4.

Exploiting Radiation-Induced Signaling to Increase the Susceptibility of Resistant Cancer Cells to Targeted Drugs: AKT and mTOR Inhibitors as an Example.

Eke I, Makinde AY, Aryankalayil MJ, Sandfort V, Palayoor ST, Rath BH, Liotta L, Pierobon M, Petricoin EF, Brown MF, Stommel JM, Ahmed MM, Coleman CN.

Mol Cancer Ther. 2018 Feb;17(2):355-367. doi: 10.1158/1535-7163.MCT-17-0262. Epub 2017 Aug 11.

5.

Disabled cell density sensing leads to dysregulated cholesterol synthesis in glioblastoma.

Kambach DM, Halim AS, Cauer AG, Sun Q, Tristan CA, Celiku O, Kesarwala AH, Shankavaram U, Batchelor E, Stommel JM.

Oncotarget. 2017 Feb 28;8(9):14860-14875. doi: 10.18632/oncotarget.14740.

6.

Pancreatic cancers require autophagy for tumor growth.

Yang S, Wang X, Contino G, Liesa M, Sahin E, Ying H, Bause A, Li Y, Stommel JM, Dell'antonio G, Mautner J, Tonon G, Haigis M, Shirihai OS, Doglioni C, Bardeesy N, Kimmelman AC.

Genes Dev. 2011 Apr 1;25(7):717-29. doi: 10.1101/gad.2016111. Epub 2011 Mar 15.

7.

Phosphorylation by casein kinase I promotes the turnover of the Mdm2 oncoprotein via the SCF(beta-TRCP) ubiquitin ligase.

Inuzuka H, Tseng A, Gao D, Zhai B, Zhang Q, Shaik S, Wan L, Ang XL, Mock C, Yin H, Stommel JM, Gygi S, Lahav G, Asara J, Xiao ZX, Kaelin WG Jr, Harper JW, Wei W.

Cancer Cell. 2010 Aug 9;18(2):147-59. doi: 10.1016/j.ccr.2010.06.015.

8.

Mig-6 controls EGFR trafficking and suppresses gliomagenesis.

Ying H, Zheng H, Scott K, Wiedemeyer R, Yan H, Lim C, Huang J, Dhakal S, Ivanova E, Xiao Y, Zhang H, Hu J, Stommel JM, Lee MA, Chen AJ, Paik JH, Segatto O, Brennan C, Elferink LA, Wang YA, Chin L, DePinho RA.

Proc Natl Acad Sci U S A. 2010 Apr 13;107(15):6912-7. doi: 10.1073/pnas.0914930107. Epub 2010 Mar 29.

9.

Pten and p53 converge on c-Myc to control differentiation, self-renewal, and transformation of normal and neoplastic stem cells in glioblastoma.

Zheng H, Ying H, Yan H, Kimmelman AC, Hiller DJ, Chen AJ, Perry SR, Tonon G, Chu GC, Ding Z, Stommel JM, Dunn KL, Wiedemeyer R, You MJ, Brennan C, Wang YA, Ligon KL, Wong WH, Chin L, dePinho RA.

Cold Spring Harb Symp Quant Biol. 2008;73:427-37. doi: 10.1101/sqb.2008.73.047. Epub 2009 Jan 15.

PMID:
19150964
10.

p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation.

Zheng H, Ying H, Yan H, Kimmelman AC, Hiller DJ, Chen AJ, Perry SR, Tonon G, Chu GC, Ding Z, Stommel JM, Dunn KL, Wiedemeyer R, You MJ, Brennan C, Wang YA, Ligon KL, Wong WH, Chin L, DePinho RA.

Nature. 2008 Oct 23;455(7216):1129-33. doi: 10.1038/nature07443.

11.

Malignant astrocytic glioma: genetics, biology, and paths to treatment.

Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L, DePinho RA, Cavenee WK.

Genes Dev. 2007 Nov 1;21(21):2683-710. Review.

12.

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies.

Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R, Stegh AH, Bradner JE, Ligon KL, Brennan C, Chin L, DePinho RA.

Science. 2007 Oct 12;318(5848):287-90. Epub 2007 Sep 13.

13.

Hdmx modulates the outcome of p53 activation in human tumor cells.

Wade M, Wong ET, Tang M, Stommel JM, Wahl GM.

J Biol Chem. 2006 Nov 3;281(44):33036-44. Epub 2006 Aug 13.

14.

A new twist in the feedback loop: stress-activated MDM2 destabilization is required for p53 activation.

Stommel JM, Wahl GM.

Cell Cycle. 2005 Mar;4(3):411-7. Epub 2005 Mar 2. Review.

PMID:
15684615
15.

Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation.

Stommel JM, Wahl GM.

EMBO J. 2004 Apr 7;23(7):1547-56. Epub 2004 Mar 18.

16.

A transactivation-deficient mouse model provides insights into Trp53 regulation and function.

Jimenez GS, Nister M, Stommel JM, Beeche M, Barcarse EA, Zhang XQ, O'Gorman S, Wahl GM.

Nat Genet. 2000 Sep;26(1):37-43. Erratum in: Nat Genet. 2005 Feb;37(2):205.

PMID:
10973245
17.

p53 regulation by post-translational modification and nuclear retention in response to diverse stresses.

Jimenez GS, Khan SH, Stommel JM, Wahl GM.

Oncogene. 1999 Dec 13;18(53):7656-65. Review.

18.
19.

v-Raf activates transcription of growth-responsive promoters via GC-rich sequences that bind the transcription factor Sp1.

Miltenberger RJ, Farnham PJ, Smith DE, Stommel JM, Cornwell MM.

Cell Growth Differ. 1995 May;6(5):549-56.

Supplemental Content

Loading ...
Support Center